Unpublished data can be of value in systematic reviews of adverse effects: Methodological overview

Journal of Clinical Epidemiology

Volumn 63, Issue 10, 2010, Pages 1071-1081

  Golder, Su ^a   Loke, Yoon K ^b   Bland, Martin ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Adverse effects; Literature review; Meta analysis; Publication bias; Systematic review; Unpublished data

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ISRADIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PROPOFOL; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; THALIDOMIDE; TICLOPIDINE;

ADVERSE DRUG REACTION; ASYSTOLE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CITATION ANALYSIS; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DATA ANALYSIS; DATA BASE; DYSPEPSIA; EVALUATION; HORMONAL THERAPY; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); METHODOLOGY; OVARY CANCER; PRIORITY JOURNAL; PUBLISHING; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; SKIN DISCOLORATION; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; THROMBOCYTOPENIC PURPURA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID DISEASE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DRUG INDUSTRY; DRUG TOXICITY; META ANALYSIS; RISK ASSESSMENT; STATISTICS;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; DRUG TOXICITY; HUMANS; META-ANALYSIS AS TOPIC; PUBLICATION BIAS; RISK ASSESSMENT;

EID: 78349250937     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2010.02.009     Document Type: Review

References (43)

1. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. York: University of York; 2009:1-281.
2. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration; 2008.
3. Song F, Eastwood A, Gilbody S, Duley L, Sutton AJ. Publication and related bias. Health Technol Assess 2000;4:1-115.
4. Price D, Jefferson T, Demicheli V. Methodological issues arising from systematic reviews of the evidence of safety of vaccines. Vaccine 2004;22:2080-4.
5. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65.
6. Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 2004;171:735-40.
7. Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A. Safety of influenza vaccines in children. Lancet 2005;366:803-4.
8. Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 2006;24:3933-8.
9. Von EE, Rollin A, Blumle A, Senessie C, Low N, Egger M. Selective reporting of outcomes of drug trials? Comparison of study protocols and published articles [abstract]. XIV Cochrane Colloquium; October 23-26, 2006; Dublin, Ireland.
10. Mahoney MR, Sargent DJ. Adverse-event rates: journals versus databases. Lancet 2007;369:171-2.
11. Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004;292: 2622-31.
12. Hemminki E. Study of information submitted by drug companies to licensing authorities. BMJ 1980;280:833-6.
13. Curfman GD, Morrissey S, Drazen MD. Expression of concern reaffirmed. N Engl J Med 2000;354:1193.
14. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," NEJM 2000:343:1520-1528.
15. Derry S, Makinson G, McQuay H, Moore A, editors. Tolerability and adverse events of celecoxib: meta-analysis of clinical trial reports. Birmingham, UK: Clinical Excellence; 2004.
16. Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med 2005;142:1090-9.
17. MooreRA,Derry S,MakinsonGT,McQuayHJ.Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644-65.
18. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA 2005;293:2131-40.
19. Cosmi B, Castelvetri C, Milandri M, Rubboli A, Conforti A. The evaluation of rare adverse drug events in Cochrane reviews: the incidence of thrombotic thrombocytopenic purpura after ticlopidine plus aspirin for coronary stenting. 8th Annual Cochrane Colloquium Abstracts; October 2000; Cape Town, Africa.
20. Hemminki E, McPherson K. Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease. Lancet 2000;355:566-9.
21. Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol 2004;57:616-21.
22. MacLean CH, Morton SC, Ofman JJ, Roth EA, Shekelle PGSouthern CE-BPC. How useful are unpublished data from the Food and Drug Administration in meta-analysis? J Clin Epidemiol 2003;56:44-51.
23. Ross SD, Kupelnick B, Kumashiro M, Arellano FM, Mohanty N, Allen IE. Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis. J Hum Hypertens 1997;11:743-51.
24. Tramer MR, Moore RA, McQuay HJ. Propofol and bradycardia: causation, frequency and severity. Br J Anaesth 1997;78:642-51.
25. Wallace AE, Neily J, Weeks WB, Friedman MJ. A cumulative meta-analysis of selective serotonin reuptake inhibitors in pediatric depression: did unpublished studies influence the efficacy/safety debate? J Child Adolesc Psychopharmacol 2006;16:37-58.
26. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341.
27. MacLean C, Morton S, Straus W, Ofman J, Roth E, Shekelle P, editors. Unpublished data from United States Food and Drug Administration New Drug Application Reviews: how do they compare to published data when assessing Nonsteroidal Antiinflammatory Drug (NSAm) associated dyspepsia? 7th Annual Cochrane Colloquium Abstracts; October 1999; Rome, Italy.
28. Golder S, Loke Y, McIntosh HM. Poor reporting and inadequate searches were apparent in systematic reviews of adverse effects. J Clin Epidemiol 2008;61:440-8.
29. Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008;178:296-305.
30. Bohlius J, Weingart O, Trelle S, Engert A. Disentangling the data: variations in data submissions from different players and their potential impact on a systematic review [abstract]. XIII Cochrane Colloquium; Oct 22-26, 2005; Melbourne, Australia. 2005:60.
31. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
32. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008;5:-217.
33. Steinberg KK, Smith SJ, Stroup DF, Olkin I, Lee NC, Williamson GD, et al. Comparison of effect estimates from a metaanalysis of summary data from published studies and from a metaanalysis using individual patient data for ovarian cancer studies. Am J Epidemiol 1997;145:917-25.
34. Hemminki E. Quality of reports of clinical trials submitted by the drug industry to the Finnish and Swedish control authorities. Eur J Clin Pharmacol 1981;19:157-65.
35. Bennett DA, Jull A. FDA: untapped source of unpublished trials. Lancet 2003;361:1402-3.
36. LaValley M, Lo G, Hunter D, Felson D. Use of the USA Food and Drug Administration web site for clinical trial information from approved therapies [abstract]. 12th Cochrane Colloquium: Bridging the Gaps; Oct 2-6, 2004; Ottawa, ON. 2004.
37. Bilker W, Gogolak V, Goldsmith D, Hauben M, Herrera G, Hochberg A, et al. Accelerating statistical research in drug safety. [letter]. Pharmacoepidemiol Drug Saf 2006;15:687-8.
38. Hauben M, Reich L, DeMicco J, Kim K. 'Extreme duplication' in the US FDA Adverse Events Reporting System database. Drug Saf 2007;30:551-4.
39. Rennie D. Fair conduct and fair reporting of clinical trials. JAMA 1999;282:1766-8.
40. Mittmann N, Knowles SR. Repetitive publication, meta-analysis, and adverse events. J Clin Psychopharmacol 1996;16:77.
41. Ioannidis JP, Chew P, Lau J. Standardized retrieval of side effects data for meta-analysis of safety outcomes. A feasibility study in acute sinusitis. J Clin Epidemiol 2002;55:619-26.
42. Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ 2005;330:753.
43. Dubben H, Beck-Bornholdt H. Systematic review of publication bias in studies on publication bias. BMJ 2005;331:433-4.